Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Anhui Zhifei BCG in Non-muscular Invasive Bladder Cancer
NCT06100653Phase 1Completed
- Sponsor
- Zhifei Biological
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Zhifei Biological. Primary endpoint: Safety and tolerability of BCG for therapeutic use at 18 months. Started Nov 2023; status: completed.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06100653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100653.